 Liminal BioSciences Inc. Nasdaq: LMNL TSX: LMNL Liminal BioSciences or the Company, a clinical-stage biopharmaceutical company, announced today that it has acquired all of the issued and outstanding shares in the capital of Fairhaven Pharmaceuticals Inc. Fairhaven, thus acquiring a preclinical research program of small molecule antagonists. Investigational therapies developed in this program target a key chemoattractant and activator of eosinophils, which play a key role in Type 2 inflammation-driven diseases through tissue repair and resolution of inflammation Fairhaven RD; Program. 